Search results for "Cardiogenic shock"

showing 10 items of 44 documents

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

2021

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required i…

Acute coronary syndromemedicine.medical_specialtyacute coronary syndrome; cardiogenic shock; glycoprotein IIb/IIIa receptor inhibitors; myocardial infarction; percutaneous coronary interventionmedicine.medical_treatmentArticleacute coronary syndromeInternal medicineAngioplastyRisk of mortalityMedicineMyocardial infarctionAdverse effectbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseaseglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionConventional PCICardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

2000

Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with metoprolol. Methods and results: Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF) < 40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete …

AdultCardiomyopathy DilatedMaleCardiac function curvemedicine.medical_specialtyCardiac VolumeAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyVentricular Function LeftDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathyHeart ratemedicineHumansProspective Studiescardiovascular diseasesAgedMetoprololHeart FailureEjection fractionbusiness.industryCardiogenic shockMiddle Agedmedicine.diseaseHeart failureExercise Testcardiovascular systemCardiologyFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesMetoprololcirculatory and respiratory physiologymedicine.drugEuropean Journal of Heart Failure
researchProduct

Successful use of impella CP through femoral access in a patient with bilateral iliac and aortic endoprosthesis in the setting of cardiogenic shock

2019

We report the case of a 67-year-old male, with previous history of severe peripheral vascular disease (abdominal aorta aneurism and bilateral iliac stenosis) requiring the implantation of 3 endoprostheses 7 months ago (Figure 1(A)), and previous myocardial infarction 10 years ago. The left ventricular ejection fraction (LVEF) was preserved at last control (58%). The patient was referred for acute coronary syndrome complicated with pulmonary oedema and cardiogenic shock. Echocardiography showed a severe impairment of LVEF (18%) and the patient was transferred to cathlab for emergency percutaneous coronary intervention (PCI). Coronary angiography via right femoral 7Fr access showed a chronic …

Atherectomy CoronaryMalemedicine.medical_specialtyProstheses and ImplantComputed Tomography AngiographyShock CardiogenicEndoprosthesiCoronary AngiographyHigh risk pciIliac ArteryPercutaneous Coronary InterventionFemoral accessmedicine.arteryCatheterization PeripheralDrug-Eluting Stentmedicinehigh risk PCIHumansAorta AbdominalAcute Coronary SyndromeImpellaPeripheral Vascular DiseasesEndovascular Procedurebusiness.industryVascular diseaseimpellaCardiogenic shockcardiogenic shockEndovascular ProceduresAbdominal aortaDrug-Eluting StentsProstheses and ImplantsGeneral MedicineMiddle Agedmedicine.diseasePeripheralSurgeryFemoral ArteryAcute Coronary Syndrome ...StenosisTreatment OutcomeCardiology and Cardiovascular MedicinebusinessActa Cardiologica
researchProduct

Impact of intra-aortic balloon counterpulsation on all-cause mortality among patients with Takotsubo syndrome complicated by cardiogenic shock: resul…

2023

Abstract Aims Takotsubo syndrome (TTS) is an acute and reversible left ventricular dysfunction and can be complicated by cardiogenic shock (CS). However, few data are available on optimal care in TTS complicated by CS. Aim of this study was to evaluate short- and long-term impact of intra-aortic balloon pumping (IABP) on mortality in this setting. Methods and results In a multi-centre, international registry on TTS, 2248 consecutive patients were enrolled from 38 centres from Germany, Italy, and Spain. Of the 2248 patients, 212 (9.4%) experienced CS. Patients with CS had a higher prevalence of diabetes (27% vs. 19%), male sex (25% vs. 10%), and right ventricular involvement (10% vs. 5%) (P …

Cardiogenic shock GEIST IABP In-hospital complications Intra-aortic balloon counter-pulsation Stress cardiomyopathy Takotsubo syndrome
researchProduct

Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care associ…

2022

Abstract Aims Cardiogenic shock (CS) is a life-threatening condition burdened by mortality in up to 50% of cases. Few recommendations exist with intermediate–low level of evidence on CS management and no data on adherence across centres exist. We performed a survey to frame CS management at multinational level. Methods and results An international cross-sectional survey was created and approved by European Society of Cardiology-Acute Cardiovascular Care Association board. A total of 337 responses from 60 countries were obtained. Data were assessed by the hospital level of care of the participants. The most common cause of CS was AMI (AMI-CS—79.9%) with significant difference according to ho…

DopamineShock CardiogenicGeneral MedicineCritical Care and Intensive Care MedicineNorepinephrineRecommendation adherenceCross-Sectional StudiesPercutaneous Coronary InterventionTreatment OutcomeDobutamineLactatesHumansCardiology and Cardiovascular MedicineSurveyCardiogenic shockMechanical and pharmacological managmentEuropean Heart Journal: Acute Cardiovascular Care
researchProduct

Death of a 23-year-old man from cardiac conduction system injury through a blunt chest impact after a car accident.

2014

Abstract Cardiac contusion, usually caused by blunt chest trauma, has been recognized with increased frequency over the past decades. Traffic accidents are the most frequent causes of cardiac contusion resulting from a direct blow to the chest. Myocardial contusion is difficult to diagnose; the clinical presentation varies greatly, ranging from a lack of symptoms to cardiogenic shock and arrhythmia. Although death is rare, cardiac contusion can be fatal. The authors report a case of death due to a cardiac conduction system injury from a blunt chest impact following a car accident. The autopsy showed no external signs of thoracic trauma, no evident rib or sternum fractures. A small sub-endoc…

Health (social science)Sternumblunt chest traumaAutopsyPathology and Forensic MedicineBluntSettore MED/43 - Medicina Legalecar accidentmedicinelcsh:Law in general. Comparative and uniform law. Jurisprudencelcsh:R5-920cardiac contusionbusiness.industryCardiogenic shockMyocardial contusionmedicine.diseaseAtrioventricular nodecardiac conduction system injurymedicine.anatomical_structureforensic pathological diagnosisAnesthesialcsh:K1-7720cardiovascular systemPresentation (obstetrics)Electrical conduction system of the heartbusinesslcsh:Medicine (General)Law
researchProduct

Good clinical practice for the use of vasopressor and inotropic drugs in critically ill patients: state-of-the-science and expert consensus

2021

Vasopressors and inotropic agents are widely used in critical care. However, strong evidence supporting their use in critically ill patients is lacking in many clinical scenarios. Thus, the Italian Society of Anesthesia and Intensive Care (SIAARTI) promoted a project aimed to provide indications for good clinical practice on the use of vasopressors and inotropes, and on the management of critically ill patients with shock. A panel of 16 experts in the field of intensive care medicine and hemodynamics has been established. Systematic review of the available literature was performed based on PICO questions. Basing on available evidence, the panel prepared a summary of evidences and then wrote…

Inotropemedicine.medical_specialtyConsensusCritical CareCritical IllnessMEDLINEshockCardiotonic AgentsCardiotonic agentsVasoconstrictor agentsCardiogenic shock; Cardiotonic agents; Septic shock; Vasoconstrictor agents03 medical and health sciences0302 clinical medicineVasoconstrictor agents030202 anesthesiologySeptic shockIntensive caremedicineHumansVasoconstrictor AgentsIntensive care medicineCardiogenic shockbusiness.industrySeptic shockCardiogenic shock030208 emergency & critical care medicinemedicine.diseaseAnesthesiology and Pain MedicinePharmaceutical PreparationsShock (circulatory)Good clinical practicemedicine.symptombusinessCardiotonic agents
researchProduct

Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicen…

2020

AbstractClinical presentation of Takotsubo syndrome (TTS) may range from acute chest pain to dyspnea: the prognostic role of clinical onset is still controversial. Aim of this study was therefore to investigate the prognostic relevance of dyspnea at presentation in patients with TTS. We analyzed 1,071 TTS patients (median age 72 years, 90% female) enrolled in the international multicenter GEIST registry. Patients were divided according to the presence or absence of dyspnea at hospital admission, as clinically assessed by the accepting physician. The primary endpoint was occurrence of in-hospital complications defined as a composite of pulmonary edema, cardiogenic shock and death. Overall, 3…

Male0301 basic medicinemedicine.medical_specialtyShock CardiogenicCardiologylcsh:MedicinePulmonary EdemaArticleacute coronary syndrome03 medical and health sciences0302 clinical medicineRisk FactorsTakotsubo CardiomyopathyInternal medicinemedicineClinical endpointtakotsubo syndromeHumansRegistriesSigns and symptomslcsh:ScienceTakotsubo syndrome (TTS) chest pain.AgedMultidisciplinaryEjection fractionbusiness.industryIncidenceIncidence (epidemiology)Cardiogenic shockHazard ratiolcsh:RAtrial fibrillationtakotsubo syndrome; dyspnea; acute coronary syndromeOdds ratioMiddle AgedPrognosismedicine.diseasePulmonary edemaHospitalizationDyspnea030104 developmental biologyFemalelcsh:Qbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

2018

IF 16.834 (2017); International audience; BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was…

MaleInotropeILL PATIENTSCardiac index030204 cardiovascular system & hematologyLACTATE0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesSUPPORTTISSUE OXYGENATIONVasoconstrictor AgentsProspective StudiesMyocardial infarctionCardiogenic shockcardiogenic shockMiddle Aged3. Good healthEpinephrineCardiologyHEARTFemaleTRIALFranceCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyShock Cardiogenicacute myocardial infarctionvasopressornorepinephrineEXTRACORPOREAL MEMBRANE-OXYGENATIONNorepinephrine (medication)03 medical and health sciencesDouble-Blind MethodInternal medicineHeart rateMANAGEMENTmedicineHumansepinephrineAgedbusiness.industrySeptic shockMORTALITYSEPTIC SHOCKHemodynamics030208 emergency & critical care medicinemedicine.disease3121 General medicine internal medicine and other clinical medicinebusiness
researchProduct

ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.

2021

Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown.Aim: To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019.Methods: In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or no…

MaleMESH: Hyperlipidemiasmedicine.medical_treatmentMESH: ComorbidityComorbidity030204 cardiovascular system & hematologyMESH: Health Care SurveysMESH: HypertensionMESH: Procedures and Techniques Utilization0302 clinical medicinePatient AdmissionInterquartile rangeMESH: Risk FactorsRisk FactorsST segmentMESH: COVID-19030212 general & internal medicineMyocardial infarctionHospital MortalityMESH: Treatment Outcomeeducation.field_of_studyMESH: Middle AgedCardiogenic shockSmokingMESH: Patient Acceptance of Health CareGeneral MedicineMESH: Heart Rupture Post-InfarctionMiddle AgedPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTreatment OutcomeHypertensionCardiologyFemaleStentsFranceCardiology and Cardiovascular MedicineSCA ST+MESH: Percutaneous Coronary Interventionmedicine.medical_specialtyMESH: PandemicsMESH: SmokingMESH: Diabetes MellitusPopulationComplications mécaniquesHyperlipidemiasRevascularizationMESH: PrognosisTime-to-TreatmentSTEMI03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineLockdownmedicineDiabetes MellitusHumansMESH: SARS-CoV-2MESH: Time-to-TreatmentMESH: Hospital MortalityMESH: ST Elevation Myocardial InfarctioneducationPandemicsHeart Rupture Post-InfarctionMESH: Humansbusiness.industryMESH: Patient AdmissionSARS-CoV-2Percutaneous coronary interventionCOVID-19Patient Acceptance of Health Caremedicine.diseaseComorbidityMESH: MaleMESH: FranceMESH: Stents[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care SurveysST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMechanical complicationsbusinessMESH: FemaleProcedures and Techniques UtilizationConfinementArchives of cardiovascular diseases
researchProduct